Добавил:
Upload Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз: Предмет: Файл:
ВИЧ ВОЗ.pdf
Скачиваний:
17
Добавлен:
27.02.2016
Размер:
5.78 Mб
Скачать

ЛЕЧЕНИЕ И ПОМОЩЬ ПРИ ВИЧ/СПИДе. КЛИНИЧЕСКИЕ ПРОТОКОЛЫ ДЛЯ ЕВРОПЕЙСКОГО РЕГИОНА ВОЗ

Библиография

1.Global tuberculosis control: surveillance, planning, financing. Geneva, WHO, 2006 (WHO/ HTM/2006.326).

2.EuroTB. Surveillance of tuberculosis in Europe: report on tuberculosis cases notified in 2003. SaintMaurice, Institut de Veille Sanitaire, 2005 (http://www.eurotb.org/rapports/2003/report_2003.htm, accessed 7 August 2006).

3.Salt J. Current trends in international migration in Europe. Strasbourg, Council of Europe, 2002 (CDMG/2002/26).

4.Hayward AC et al. Epidemiology and control of tuberculosis in western European cities. International

Journal of Tuberculosis and Lung Diseases, 2003, 7:751–757.

5.WHO/IUATLD global project on anti-tuberculosis drug resistance surveillance. Anti-tuberculosis drug resistance in the world: report no. 3. Geneva, WHO, 2004 (WHO/HTM/TB/2004.343).

6.Aebi MF. Space 1 (Council of Europe Annual Penal Statistics) Survey 2004. Strasbourg, Council of Europe, 2005.

7.Drobniewski F. Tuberculosis in prisons – forgotten plague. The Lancet, 1995, 346:948–949.

8.BoneAet al. Tuberculosis control in prisons: a manual for programme managers. Geneva, WHO, 2000 (WHO/CDS/TB/2000.281).

9.Drobniewski FAet al. Tuberculosis, HIV seroprevalence and intravenous drugs abuse in prisoners. The

European Respiratory Journal, 2005, 26:298–304.

10.de Colombani P. Overview of the tuberculosis situation in the European Region with a focus on prisons.

11th Annual Meeting and Conference of the WHO European Network for Prison and Health: the Next 10 Years, London, 17–18 October 2005.

11.European Centre for the Epidemiological Monitoring of AIDS (EuroHIV). HIV/AIDS surveillance in Europe: end-year report 2004. Saint-Maurice, Institut de Veille Sanitaire, 2005 (No. 71; http://www. eurohiv.org/reports/report_71/pdf/report_eurohiv_71.pdf, accessed 29 September 2006).

12.Corbett EL et al. The growing burden of tuberculosis: global trends and interactions with the HIV epidemic. Archives of Internal Medicine, 2003, 163:1009–1021.

13.Interim policy on collaborative TB/HIV activities. Geneva, WHO, 2004 (WHO/HTM/HIV/2004.1).

14.de Colombani P et al. European framework to decrease the burden of TB/HIV. Copenhagen, WHO Regional Office for Europe, 2003 (WHO/EURO/03/5037600).

15.TB/HIV: a clinical manual, 2nd ed. Geneva, WHO, 2004 (WHO/HTM/TB/2004.329).

16.Lienhardt C, Rodriques LC. Estimation of the impact of the human immunodeficiency virus infection on tuberculosis: tuberculosis risks revised? International Journal of Tuberculosis and Lung Diseases, 1997, 1(3):196–204.

17.Hopewell PC, Chaisson RE. Tuberculosis and human immunodeficiency virus infection. In: Reichman LB, Hershfield ES, eds. Tuberculosis: a comprehensive international approach. New York, Marcel Dekker, 2000:525–547 (Lung Biology in Health and Disease Series, Vol. 144).

18.Girardi E et al. Impact of the HIV epidemic on the spread of other diseases: the case of tuberculosis. AIDS, 2000, 14(Suppl. 3):S47–S56.

19.Cruciani M et al. The impact of HIV1 on infectiousness of tuberculosis: a metaanalysis. Clinical Infec­ tious Diseases, 2001, 33:1922–1930.

20.Castro KG, Dooley SW, Curran JW. Transmission of HIV-associated tuberculosis to health-care workers. The Lancet, 1992, 340(8826):1043–1044.

21.AckahAN et al. Response to treatment, mortality and CD4 lymphocyte counts in HIV-infected persons with tuberculosis in Abidjan. AIDS, 1995, 9:1251–1254.

22.Harries AD et al. Deaths from tuberculosis in Sub-Saharan African countries with a high prevalence of HIV-1. The Lancet, 2001, 357(9267):1519–1529).

23.Elliott AM et al. The impact of human immunodeficiency virus on mortality of patients treated for tuberculosis in a cohort study in Zambia. Transactions of the Royal Society of Tropical Medicine and Hygiene, 1995, 89:78–82.

24.Badri M et al. Association between tuberculosis and HIV disease progression in a high tuberculosis prevalence area. The International Journal of Tuberculosis and Lung Disease, 2001, 5:225–232.

25.Drobniewski F et al. Increasing trends in HIV and TB rates in Odessa and the Ukraine. International

Journal of STD & AIDS, 2005, 16:374–378.

26.WHO, Joint United Nations Programme on HIV/AIDS (UNAIDS). Policy statement on preventive therapy against tuberculosis in people living with HIV: report of a meeting held in Geneva, 18–20 Feb­ ruary 1998. Geneva, WHO, 1998 (WHO/TB/98.255; UNAIDS/98.34).

166

Туберкулез и ВИЧ-инфекция: тактика ведения пациентов с сочетанной инфекцией

27.Fitzgerald DW et al. Active tuberculosis in individuals infected with human immunodeficiency virus after isoniazid prophylaxis. Clinical Infectious Diseases, 2000, 31:1495–1497.

28.TB/HIVresearchprioritiesinresource-limitedsettings:reportofanexpertconsultation.Geneva,WHO, 2005 (WHO/HIV/2005.03).

29.Treatment of tuberculosis: guidelines for national programmes, 3rd ed. Geneva, WHO, 2003 (http:// whqlibdoc.who.int/hq/2003/WHO_CDS_TB_2003.313_eng.pdf, accessed 4 April 2006).

30.Dean GL et al. Treatment of tuberculosis in HIV-infected persons in the area of highly active antiretroviral therapy. AIDS, 2002, 16(1):75–83.

31.Scaling up antiretroviral therapy in resource-limited settings: treatment guidelines for a public health approach, 2003 rev. Geneva, WHO, 2004.

32.Benson CAet al. Treating opportunistic infections among HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health and the HIV Medicine Association/Infectious Disease Society of America. , 2004, 53(RR-15):S131–S235.

33.Fujiwara PI, Clevenbergh P, Dlodlo RA. Management of adults living with HIV/AIDS in low-income, high-burden settings with special reference to persons with tuberculosis. International Journal of Tu­ berculosis and Lung Diseases, 2005, 9(9):946–958.

34.PozniakAL et al. BHIVA treatment guidelines for TB/HIV infection. The British HIVAssociation, London, 2005 (http://www.bhiva.org/guidelines/2005/tbhiv.html, accessed 8 June 2006).

35.Almond L et al. A retrospective survey of the Liverpool TDM Service: factors influencing efavirenz concentrations in patients taking rifampicin. 6th International Workshop on Clinical Pharmacology of HIV Therapy, Quebec, April 2005 (Poster 2.12).

36.Manosuthi W et al. A randomized controlled trial of efavirenz 600 mg/day versus 800 mg/day in HIV-infected patients with tuberculosis to study plasma efavirenz level, virological and immunological outcomes: a preliminary result. In: XV International AIDS Conference. Bangkok, 2004 (Abstract MoOrB1013).

37.Sheehan NL, Richter C. Efavirenz 600 mg is not associated with subtherapeutic efavirenz concentrations when given concomitantly with rifampin. 6th International Workshop on Clinical Pharmacology of HIV Therapy, Quebec, 28–30 April 2005.

38.Kearney BP et al. Didanosine and tenofovir DF drug-drug interaction: assessment of didanosine dose reduction. Tenth Conference on Retroviruses and Opportunistic Infections, Boston, Feb 10-14 (Abstract 533).

39.Kaul S et al. Pharmacokinetic evaluation of reduced doses of didanosine enteric coated capsules (ddI EC) in combination with tenofovir disoproxil fumarate (TDF) and food for a once daily antiretroviral regimen. Fourth International Workshop on Clinical Pharmacology of HIV therapy, Cannes, March 27-29 2003 (Abstract 54).

40.Centers for Disease Control. Updated guidelines for the use of rifabutin or rifampin for the treatment and prevention of tuberculosis among HIV-infected patients taking protease inhibitors. Morbidity and

Mortality Weekly Report, 2000, 49:185–189.

41.Ribera A, Azuaje C, Montero F. Saquinavir, ritonavir, didanosine, and lamivudine in a once daily regimen for HIV infection in patients with rifampicin-containing antituberculosis treatment. In: XVI Inter­ national AIDS Conference. Barcelona, 2002 (Abstract ThPeB 7280).

42.Ribera E et al. Pharmacokinetic interaction between nevirapine and rifampicin in HIV-infected patients with tuberculosis. Journal of Acquired Immune Deficiency Syndrome, 2001, 28:450–453.

43.WHO HIV/AIDS. Evidence for action: effectiveness of community-based outreach in preventing HIV/ AIDS among injecting drug users. Geneva, WHO, 2004.

44.Purcell DW et al. Interventions for seropositive injectors research and evaluation: an integrated behavioural intervention with HIV-positive injection drug users to address medical care, adherence and risk reduction. Journal of Acquired Immune Deficiency Syndrome, 2004, 37:S110–S118.

45.Verwell G et al. Treatment with highly active antiretroviral therapy in human immunodeficiency virus type 1-infected children is associated with a sustained effect on growth. Pediatrics, 2002, 109(2) (http:/ www.pediatrics.org/cgi/content/full/109/2/e25, accessed 4 April 2006).

46.Furrer H, Malinverni R. Systemic inflammatory reaction after starting highly active antiretroviral therapy in AIDS patients treated for extrapulmonary tuberculosis. American Journal of Medicine, 1999, 106:371–372.

47.Narita M et al. Paradoxical worsening of tuberculosis following antiretroviral therapy in patients with AIDS. American Journal of Respiratory and Critical Care Medicine, 1998, 158(1):157–161.

167

ЛЕЧЕНИЕ И ПОМОЩЬ ПРИ ВИЧ/СПИДе. КЛИНИЧЕСКИЕ ПРОТОКОЛЫ ДЛЯ ЕВРОПЕЙСКОГО РЕГИОНА ВОЗ

48.Kumarasamy N et al. Incidence of immune reconstitution syndrome in HIV/tuberculosis-coinfected patients after initiation of generic antiretroviral therapy in India. Journal of Acquired Immune Deficiency Syndrome, 2004, 37(5):1574–1576.

49.Lawn SD, Bekker L, Miller RF. Immune reconstitution disease associated with mycobacterial infections in HIV-infected individuals receiving antiretrovirals. The Lancet Infectious Diseases, 2005, 5(6):361–

373.

50.Bartlett JA.Addressing the challenges of adherence. JournalofAcquiredImmuneDeficiencySyndrome, 2002, 29:S2–S10.

51.Lange JMA et al. What policymakers should know about drug resistance and adherence in the context of scaling-up treatment of HIV infection. AIDS, 2004, 18(suppl 3):S69–S74.

52.A guide to monitoring and evaluation for collaborative TB/HIV activities. Field test version. Geneva, WHO, 2004 (WHO/HIV/2004.09).

53.Treatment of tuberculosis: guidelines for national programmes, 3rd ed. Geneva, WHO, 2003:55 (http:// whqlibdoc.who.int/hq/2003/WHO_CDS_TB_2003.313_eng.pdf, accessed 4 April 2006).

168

Соседние файлы в предмете [НЕСОРТИРОВАННОЕ]